FDA vaccine studies censored by Trump admin after finding benefits of shots

特朗普政府审查 FDA 疫苗研究，此前研究证实了疫苗的益处

Despite Health Secretary Robert F. Kennedy’s pledge to provide “radical transparency,” the agencies under his control continue to suppress scientific research that conflicts with his anti-vaccine agenda. 尽管卫生部长小罗伯特·F·肯尼迪（Robert F. Kennedy Jr.）承诺提供“彻底的透明度”，但他所管辖的机构仍在继续压制那些与其反疫苗议程相冲突的科学研究。

On Tuesday, The New York Times reported confirmation from the Department of Health and Human Services that the Food and Drug Administration had blocked the publication of studies showing the safety and efficacy of vaccines against COVID-19 and shingles. 周二，《纽约时报》援引美国卫生与公众服务部（HHS）的证实报道称，食品药品监督管理局（FDA）阻止了多项研究的发表，这些研究旨在展示新冠疫苗和带状疱疹疫苗的安全性和有效性。

The revelation follows a report from The Washington Post last month that the Centers for Disease Control and Prevention scrapped a scientifically vetted study previously scheduled for publication that found COVID-19 vaccines sharply cut the risk of emergency care and hospitalization among healthy adults. The study was ultimately rejected by Kennedy’s acting CDC director, who claimed to have concerns about the study’s methodology. 在此之前，《华盛顿邮报》上个月曾报道称，疾病控制与预防中心（CDC）废弃了一项原定发表、且已通过科学审查的研究。该研究发现，新冠疫苗显著降低了健康成年人接受急诊和住院治疗的风险。这项研究最终被肯尼迪任命的 CDC 代理主任否决，理由是其对研究方法存在疑虑。

Similarly at the FDA, two studies on COVID-19 vaccines by agency scientists were accepted for publication at medical journals, according to the Times. But unnamed FDA officials directed the agency scientists to withdraw the studies. 据《纽约时报》报道，在 FDA 也发生了类似情况：该机构科学家撰写的两项关于新冠疫苗的研究已被医学期刊接受发表，但未具名的 FDA 官员指示这些科学家撤回了研究。

While a preliminary abstract of one of the studies presented at a conference last fall remains online, the Times obtained a copy of the full manuscript, the conclusion of which reads, “Given the available evidence, FDA continues to conclude the benefits of vaccination outweigh the risks.” 尽管其中一项研究在去年秋季会议上展示的初步摘要仍可在网上查阅，但《纽约时报》获得了一份完整手稿的副本，其结论写道：“根据现有证据，FDA 依然认为接种疫苗的益处大于风险。”

In addition, the Times learned that FDA officials did not allow agency scientists to submit two abstracts for studies on Shingrix, a shingles vaccine, to a major drug safety conference. The studies reportedly bolstered known efficacy and safety data of the vaccines. 此外，《纽约时报》获悉，FDA 官员不允许该机构科学家向一个主要的药物安全会议提交两份关于带状疱疹疫苗 Shingrix 的研究摘要。据报道，这些研究进一步支持了该疫苗已知的有效性和安全性数据。

HHS spokesperson Andrew Nixon said in a statement that the axed COVID studies “were withdrawn because the authors drew broad conclusions that were not supported by the underlying data. The FDA acted to protect the integrity of its scientific process and ensure that any work associated with the agency meets its high standards.” HHS 发言人安德鲁·尼克松（Andrew Nixon）在一份声明中表示，被撤销的新冠研究“之所以被撤回，是因为作者得出的广泛结论缺乏基础数据的支持。FDA 此举是为了保护其科学程序的完整性，并确保与该机构相关的任何工作都符合其高标准。”

Of the shingles study looking at efficacy, he said, “The design of that study fell outside the agency’s purview.” Nixon did not address why the Shingrix safety study was withheld. 关于那项研究有效性的带状疱疹研究，他表示：“该研究的设计超出了本机构的职权范围。”尼克松并未说明为何要扣留 Shingrix 的安全性研究。